Researchers found that state-level regulations significantly impact the uptake of biosimilar insulin, with more permissive laws leading to greater use of interchangeable alternatives.
Researchers found that state-level regulations significantly impact the uptake of biosimilar insulin, with more permissive laws leading to greater use of interchangeable alternatives.
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
